Home Cytoskeletal Signaling Integrin

Integrin Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S8594 Tirofiban Hydrochloride Tirofiban Hydrochloride (MK-383) is the hydrochloride salt form of tirofiban, a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation. It is more soluable than Tirofiban.
J Immunother Cancer, 2024, 12(11)e009805
Transl Oncol, 2024, 39:101813
Front Cell Infect Microbiol, 2021, 11:783085
E0462 Pyrintegrin Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.
Nat Commun, 2025, 16(1):5461
Signal Transduct Target Ther, 2024, 9(1):109
S3085 Tirofiban Tirofiban (MK-383) is a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.
Food Funct, 2020, 11(1):139-152
E4615 GLPG0187 GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. This compound also inhibits migrasome biogenesis without cytotoxicity. It exhibits potent antitumor activity.
Sci Rep, 2025, 15(1):9147
S4513 RGD peptide (GRGDNP) RGD peptide (GRGDNP) is an inhibitor of binding of integrins to the extracellular matrixs. This compound induces apoptosis presumably through direct activation of caspase-3.
Tradit Med Res, 2023, 8(9):50
S6840 OSU-T315 OSU-T315 (ILK-IN-2) is a potent Integrin-Linked Kinase (ILK) inhibitor with IC50 of 0.6 μM. This compound induces autophagy and apoptosis, both of which are integral to its antiproliferative activity. It exhibits anti-tumor activity.
Exp Eye Res, 2023, 234:109609
E1558 GSK-3008348 HCl GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
S0314 TR-14035 TR-14035 (SB 683698, MDK-1191) is a a dual alpha4beta (α4β) integrin antagonist with IC50 of 7 nM and 87 nM for alpha4beta7 (α4β7) and alpha4beta1 (α4β1), respectively.
E0790 ILK-IN-3 ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.
E7334 Cyclo(RGDyK) Cyclo(RGDyK) is a potent and selective inhibitor of αVβ3 integrin . It significantly reduces lung inflammation and fibrosis induced by influenza A virus, and improves lung morphology, lowers pulmonary fibrosis scores, and suppresses the expression of αVβ3, TGF-β1, NF-κB p65, p38 MAPK, and HIF-1α, confirming its protective effects against ALI and pulmonary fibrosis.
E6559New GS-1427 GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease.
E7759 GRGDSP GRGDSP is a fibronectin-derived peptide and an inhibitor of Integrin. It can be used for surface modification of cardiovascular implants, such as vascular grafts, to promote endothelialization, and also holds potential for hepatocellular carcinoma (HCC) treatment by inhibiting tumor cell adhesion and limiting metastasis.
E1385 Bexotegrast (PLN-74809) Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).
S3408 A286982 A-286982 is a potent, nonpeptide inhibitor of LFA-1/ICAM-1 interaction with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.